ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 171 filers reported holding ASCENDIS PHARMA A/S in Q4 2021. The put-call ratio across all filers is 1.59 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2024 | $483,744 | -37.0% | 3,200 | -47.5% | 0.00% | -50.0% |
| Q4 2023 | $768,295 | +134.4% | 6,100 | +74.3% | 0.00% | – |
| Q3 2023 | $327,740 | -8.2% | 3,500 | -12.5% | 0.00% | -100.0% |
| Q2 2023 | $357,000 | -84.7% | 4,000 | -81.7% | 0.00% | -80.0% |
| Q1 2023 | $2,337,396 | +18.9% | 21,800 | +35.4% | 0.01% | -16.7% |
| Q4 2022 | $1,966,293 | +495.8% | 16,100 | +403.1% | 0.01% | +500.0% |
| Q3 2022 | $330,000 | -9.1% | 3,200 | -17.9% | 0.00% | 0.0% |
| Q2 2022 | $363,000 | -74.2% | 3,900 | -67.5% | 0.00% | -80.0% |
| Q1 2022 | $1,408,000 | +110.5% | 12,000 | +185.7% | 0.01% | +66.7% |
| Q3 2021 | $669,000 | +58.9% | 4,200 | +31.2% | 0.00% | +50.0% |
| Q2 2021 | $421,000 | -16.3% | 3,200 | -17.9% | 0.00% | 0.0% |
| Q1 2021 | $503,000 | +11.8% | 3,900 | +44.4% | 0.00% | 0.0% |
| Q4 2020 | $450,000 | – | 2,700 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RA Capital Management | 4,240,536 | $300,484,000 | 16.06% |
| Sofinnova Investments, Inc. | 2,479,514 | $175,698,000 | 15.66% |
| Vivo Capital, LLC | 2,166,832 | $153,542,000 | 15.48% |
| VHCP Management II, LLC | 504,210 | $35,728,000 | 9.54% |
| EcoR1 Capital, LLC | 1,087,257 | $77,043,000 | 6.94% |
| Avoro Capital Advisors LLC | 1,963,336 | $139,122,000 | 6.39% |
| Foresite Capital Management IV, LLC | 245,424 | $17,391,000 | 5.70% |
| Eventide Asset Management | 1,544,900 | $109,472,000 | 4.02% |
| Orbimed Advisors | 4,155,891 | $294,486,000 | 3.55% |
| Ghost Tree Capital, LLC | 225,000 | $15,944,000 | 3.39% |